Clonal heterogeneity in human pancreatic ductal adenocarcinoma and its impact on tumor progression.

Clonal heterogeneity in human pancreatic ductal adenocarcinoma includes multiple genetically distinct neoplastic clones within individual tumors, with MYC amplification linked to tumor progression.

• Why it matters: Understanding how cellular and genetic diversity contributes to PDAC biology is crucial because it influences tumor behavior, immune evasion, and metastasis, which are not fully captured by bulk sequencing.
• What they did: The study analyzed 62 primary PDAC tumors using single-cell RNA sequencing of 443,451 cells, including spatial transcriptomics and matched pre- and post-chemotherapy samples, to map clonal, transcriptional, and spatial heterogeneity.
• The result: Findings show clone-specific ligand-receptor programs modulated by genomic dosage, with MYC amplification associated with classical-to-basal transitions and immune depletion; MYC knockdown reactivates classical programs, suggesting potential therapeutic targets.